Skip to main content
EuBiologics Co., Ltd. logo

EuBiologics Co., Ltd. — Investor Relations & Filings

Ticker · 206650 ISIN · KR7206650004 KO Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2022-08-12 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 206650

About EuBiologics Co., Ltd.

http://eubiologics.com/eng/

EuBiologics Co., Ltd. is a biopharmaceutical company focused on improving global public health through the development and supply of safe and effective vaccines. The company specializes in preventative vaccines against global pandemics and emerging infectious diseases, with a key product being its oral cholera vaccine. In addition to its vaccine pipeline, EuBiologics provides Contract Research and Manufacturing Organization (CRMO) services. These services cover the development and GMP-compliant production of mammalian cell and microbial-derived biopharmaceuticals, including protein-based therapeutics and antibodies. The company is committed to technological innovation and adhering to international standards to address global health challenges.

Recent filings

Filing Released Lang Actions
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company 'EuBiologics Co., Ltd.' covering the period from January 1, 2022, to June 30, 2022. It contains detailed financial statements, management discussion, and corporate information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2022
2022-08-12 Korean
투자판단관련주요경영사항(코로나19 치료제·백신 신약개발사업의 국책과제 선정)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Genexine) regarding a clinical trial suspension/discontinuation (GX-19). It details the reason for the suspension, the financial impact on the company's equity, and the expected future actions. Since it is a specific regulatory announcement regarding a material business event (clinical trial status) and does not fit into categories like financial reports, dividends, or board changes, it is classified as a general regulatory filing.
2022-08-02 Russian
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an executive (Kim Deok Sang) of Eubiologics. This type of filing, which details personal share transactions by company directors and executives, is classified as a Director's Dealing report.
2022-07-06 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, including major shareholding notifications, changes in special relationships, and details of stock-related contracts (such as collateral and repurchase agreements). This falls under the 'Major Shareholding Notification' category.
2022-07-06 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Correction Report' (정정신고) for a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결). It details changes to contract dates and terms due to COVID-19 supply chain issues. Since this is a specific regulatory disclosure regarding a material contract update that does not fit into the other specialized categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2022-07-01 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Single Sales/Supply Contract' amendment. It details a change in the contract end date for a vaccine supply agreement with UNICEF. Since this is a specific regulatory disclosure regarding a material contract update (a 'Major Disclosure' or 'Susi Gongsi' in the Korean market context) and does not fit into categories like financial reports, dividends, or management changes, it falls under the general regulatory filing category.
2022-06-22 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.